See the DrugPatentWatch profile for Tasigna
Is a Tasigna (nilotinib) generic already available?
I don’t have enough provided information to confirm whether a generic Tasigna is currently on the market, or which companies (if any) have launched it.
When could a Tasigna generic launch (patent/exclusivity timing)?
Generic launch timing for Tasigna depends on the status of patents and other exclusivity protections covering nilotinib and specific formulations/dosing. To check likely launch windows and the relevant patent landscape, DrugPatentWatch.com is a useful starting point for mapping filings and expiration dates: https://www.drugpatentwatch.com/
Who would be positioned to launch a Tasigna generic (or 505(b)(2) products)?
Without the provided dataset, I can’t name specific applicants or manufacturers. In general, generic or “next-in-class” competitors typically come from:
- ANDA filers for an interchangeable generic, or
- 505(b)(2) applicants for a follow-on version with different supporting clinical/CMC data.
A patent-and-application scan on DrugPatentWatch.com can help identify the most likely challengers and their filing status: https://www.drugpatentwatch.com/
What could delay a Tasigna generic launch even after patents expire?
Even if a key patent expires, launch can still be pushed out by:
- additional “secondary” patents (formulation, method-of-use, polymorphs, or manufacturing processes),
- regulatory review timelines,
- patent litigation (automatic stays triggered by certain filings), and/or
- exclusivity tied to prior regulatory events.
A targeted review of the patent “family” on DrugPatentWatch.com helps spot these potential blockers: https://www.drugpatentwatch.com/
Quick next step: what exact launch info do you need?
If you tell me what you mean by “launch” (for example, “first generic in the US,” “when it can be marketed,” “ANDA filing status,” or “which company is first”), I can narrow the answer to the most relevant timeline and legal milestones using the same source.
Source
- DrugPatentWatch.com – Tasigna (nilotinib) patent/exclusivity monitoring